Terbinafine hydrochloride and Visual impairment - a phase IV clinical study of FDA data

Summary:

Visual impairment is found among people who take Terbinafine hydrochloride, especially for people who are male, 50-59 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Terbinafine hydrochloride and have Visual impairment. It is created by eHealthMe based on reports of 1,197 people who have side effects when taking Terbinafine hydrochloride from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 18, 2023

1,197 people reported to have side effects when taking Terbinafine hydrochloride.
Among them, 9 people (0.75%) have Visual impairment.

What is Terbinafine hydrochloride?

Terbinafine hydrochloride has active ingredients of terbinafine hydrochloride. It is often used in fungal infection. eHealthMe is studying from 1,734 Terbinafine hydrochloride users for its effectiveness, alternative drugs and more.

What is Visual impairment?

Visual impairment is found to be associated with 2,856 drugs and 2,302 conditions by eHealthMe.

Number of Terbinafine hydrochloride and Visual impairment reports submitted per year:

Could Terbinafine hydrochloride cause Visual impairment?

Time on Terbinafine hydrochloride when people have Visual impairment *:

Gender of people who have Visual impairment when taking Terbinafine hydrochloride *:

female: 33.33 %
male: 66.67 %

Age of people who have Visual impairment when taking Terbinafine hydrochloride *:

Common drugs people take besides Terbinafine hydrochloride *:

Common side effects people have besides Visual impairment *:

Nausea (feeling of having an urge to vomit): 5 people, 55.56%
Depression: 3 people, 33.33%
Hair Loss: 3 people, 33.33%
Drug Ineffective: 3 people, 33.33%
Rashes (redness): 3 people, 33.33%
Itching: 3 people, 33.33%
Weakness: 2 people, 22.22%
Fatigue (feeling of tiredness): 2 people, 22.22%
Hypersensitivity: 2 people, 22.22%
Gastritis (inflammation of stomach): 2 people, 22.22%

Common conditions people have *:

Staphylococcal Infection (an infection with staphylococcus bacteria): 2 people, 22.22%
Scedosporium Infection (a filamentous fungus which occasionally causes infections in humans): 2 people, 22.22%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 2 people, 22.22%
Pain: 2 people, 22.22%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 22.22%
Pulmonary Mycosis (lung infection caused by yeast-like fungi): 1 person, 11.11%
Osteomyelitis (infection of bone): 1 person, 11.11%
Arthritis Infective (purulent invasion of a joint by an infectious agent which produces arthritis): 1 person, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Terbinafine hydrochloride and have Visual impairment?

Check whether Visual impairment is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Visual impairment treatments and more:

Visual impairment (107,679 reports)

COVID vaccines that are related to Visual impairment:

Common drugs associated with Visual impairment:

All the drugs that are associated with Visual impairment:

Visual impairment (2,856 drugs)

Common conditions associated with Visual impairment:

All the conditions that are associated with Visual impairment:

Visual impairment (2,302 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on terbinafine hydrochloride (the active ingredients of Terbinafine hydrochloride) and Terbinafine hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.